Showing results (201-210 of 234) with videos related to

Sort By:
Pageof 24
Expert Opinion on Biological Therapy|November 21, 2014
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysisNicola Silvestris, Mario Scartozzi, Giusi Graziano, et al.
Pancreas|May 18, 2018
Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter AnalysisOronzo Brunetti, Giuseppe Aprile, Paolo Marchetti, et al.
Lancet (London, England)|March 6, 2015
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Sabino De Placido, Paolo Bruzzi, et al.
The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
The Clinical Journal of Pain|February 6, 2015
Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settingsSebastiano Mercadante, Marzia Lazzari, Carlo Reale, et al.
Journal of Thrombosis and Haemostasis : JTH|May 13, 2020
Thrombin generation predicts early recurrence in breast cancer patientsMarina Marchetti, Cinzia Giaccherini, Giovanna Masci, et al.
Oncotarget|May 26, 2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort studyElena Verzoni, Ugo De Giorgi, Lisa Derosa, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Pageof 24